Terry's Desk4 days ago3 min readTerry's CornerTarget Residence Time: The Hidden Driver of In Vivo Efficacy
Terry's DeskAug 123 min readTerry's CornerMisread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Terry's DeskAug 53 min readTerry's CornerWhy Intracellular Drugs May Hold the Key to GPCR Therapeutics
Terry's DeskJul 293 min readTerry's CornerGPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Terry's DeskJun 301 min readTerry's CornerIs Your Agonist Really “Working”—Or Are You Just Seeing What Your System Allows?
Terry's DeskJun 301 min readTerry's CornerWhat If the Most Important Part of Your Drug Isn’t What It Binds—But What It Does?
Terry's DeskJun 301 min readTerry's CornerWhat If Your Data is Lying to You? The Calcium Assay Dilemma
Terry's DeskJun 241 min readTerry's CornerFrom Ox Liver to AI: How the History of Pharmacology Shapes Its Future
Terry's DeskJun 221 min readTerry's CornerUnlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
